Biodesix, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Scott Hutton
- Full Time Employees
- 334
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 919 West Dillon Road Louisville CO United States of America 80027
- IPO Date
- Oct 28, 2020
- CIK
- 0001439725
- Website
- biodesix.com
- Similar Companies
- Business
- Biodesix, Inc. Biodesix, Inc. (Nasdaq: BDSX) provides blood-based molecular diagnostic testing and development services focused on lung disease and oncology. Founded in 2005 and headquartered in Louisville, Colorado, the company operates primarily in the United States through CLIA-certified laboratories, offering diagnostic solutions that integrate genomics, proteomics, transcriptomics, and radiomics via its proprietary Diagnostic Cortex AI platform. Its core products include the Nodify Lung portfolio with Nodify XL2 and Nodify CDT tests for lung nodule malignancy risk assessment; the IQLung strategy encompassing GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests for advanced non-small cell lung cancer therapy guidance; and biopharmaceutical services such as companion diagnostic development, clinical trial testing, biomarker discovery, and regulatory support. Biodesix serves pulmonologists, thoracic surgeons, oncologists, and biopharma clients, emphasizing non-invasive blood tests to enable personalized treatment decisions and reduce unnecessary procedures. Recent developments include an expanded partnership with Bio-Rad Laboratories in October 2025 to develop and validate Droplet Digital PCR assays, notably the ddPLEX ESR1 mutation detection assay for advanced breast cancer on the QX600 platform; designation as a Thermo Fisher Scientific Center of Excellence for NGS diagnostics in August 2025; a one-for-twenty reverse stock split in September 2025; and a $55 million oversubscribed common stock and private placement financing in April 2024 to support commercial expansion, R&D, and product pipeline advancement.
Company News
Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026
Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Recommendation of “Moderate Buy” by Analysts
Biodesix to Participate in Upcoming Investor Conferences
What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now?
Wall Street Analysts See a 26.72% Upside in Biodesix (BDSX): Can the Stock Really Move This High?
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference
Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue?
Wall Street Analysts Think Biodesix (BDSX) Could Surge 31.91%: Read This Before Placing a Bet
Biodesix, Inc. (BDSX) Q2 2026 Earnings Call Transcript
Biodesix Q2 Earnings Call Highlights
Biodesix, Inc. (BDSX) Reports Q2 Loss, Beats Revenue Estimates
Biodesix Announces Second Quarter 2026 Results and Highlights
Biodesix to Participate in Canaccord Genuity's 46th Annual Growth Conference
BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
Biodesix, Inc. (NASDAQ:BDSX) Receives $28.33 Consensus PT from Brokerages